A di­ag­nos­tics com­pa­ny com­pletes its phar­ma makeover, re­brand­ing as Fore with Im­munomedics vet at the helm

Fore! Watch out, there’s a biotech in town that’s got a new name.

The Is­raeli di­ag­nos­tics com­pa­ny Nov­el­lus has un­der­gone a re­brand­ing, mak­ing the tran­si­tion to phar­ma­ceu­ti­cals as Fore Bio­ther­a­peu­tics, the com­pa­ny an­nounced Mon­day. As part of the change in di­rec­tion, Fore has ap­point­ed Us­ama Ma­lik as CEO, a for­mer key play­er at Im­munomedics dur­ing their $21 bil­lion ac­qui­si­tion by Gilead.

Though they have made the full turn to­ward ther­a­peu­tics, Fore’s busi­ness mod­el does not fo­cus on drug dis­cov­ery, Ma­lik told End­points News. Rather, the com­pa­ny is plan­ning to uti­lize its ge­nomics-based plat­form to in-li­cense pro­grams and screen them to see where they could be best put to use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER